Ausschlusskriterien
Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as > 3-4 times/month (ibuprofen and nimesulide will be permitted).
boolean
Patient has primary or secondary amyloidosis.
boolean
Patient has TTR-associated amyloidosis with V30M mutation.
boolean
If female, patient is pregnant or breast feeding.
boolean
Patient has received prior liver transplantation.
boolean
Patient is expected to undergo liver transplantation within 12 months after enrollment.
boolean
Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).
boolean
Patient has renal insufficiency (creatinine clearance < 30 ml/min).
boolean
Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) > 2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease.
boolean
Patient has a New York Heart Association (NYHA) Functional Classification >= III.
boolean
Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).
boolean
Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g., symptomatic left ventricular dysfunction from any cause other than amyloid, patients with a primary diagnosis of symptomatic valvular heart disease)
boolean
Patient has a co-morbidity anticipated to limit survival to < 12 months.
boolean
Patient has received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline (Day 0).
boolean